Ovarian Cancer Initiative at Michigan Medicine Receives Bequest
The Ovarian Cancer Initiative at Michigan Medicine, led by Karen McLean, MD, PhD, has received a generous bequest from Beth J. Johnson.
Read about the Ovarian Cancer Initiative.
Collaborative Research Reveals New Insights into Aromatase Inhibitor Side Effects
This Michigan Health Blog highlights collaborative research between Dr. McLean's Gynecologic Oncology team and other Rogel Cancer Center providers, looking into the use and side-effects of aromatase inhibitors in gynecologic cancer patients.
Find the original research paper on Pubmed.
Dr. McLean Featured in The ASCO Post
Dr. Karen McLean provided an expert point of view on the TROPHIMMUN Trial, a new treatment approach for gestational trophoblastic tumors in patients who have not responded to first-line chemotherapy, for The ASCO Post.
McLean Laboratory Awarded R01 Grant from the National Cancer Institute
Karen McLean, MD, PhD, was awarded $1.8 million by the National Cancer Institute and National Institutes of Health for her R01, "Sensitizing High Grade Serous Cancers to Immunotherapy through the Induction of DNA Damage." Project Co-Investigators include Yu Lei, DDS, PhD, Department of Periodontics and Oral Medicine, Kathleen Cho, MD, Department of Pathology, and Rong Wu, MD, Department of Pathology. Weiping Zou, MD, PhD, Department of Surgery, is a consultant on the project.
Learn about this project at the NIH Reporter.
Ovarian Cancer Symptoms and Risk Factors to Know
This Michigan Medicine article discusses important facts and features of ovarian cancer.
A Patient's Experience with Ovarian Cancer
A Rogel Cancer Center ovarian cancer patient and her experiences are shared in this Michigan Medicine article for Ovarian Cancer Awareness Month in September 2018.